SCOPUS 정보 검색 플랫폼

Volumn 60, Issue 14, 2000, Pages 3717-3721

Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil rats bearing advanced colorectal cancer: Role of drug sequence and dose

(2) Cao, S a Rustum, Y M a

a ROSWELL PARK CANCER INSTITUTE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; KINETICS; MAXIMUM TOLERATED DOSE; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 0034660888 PISSN: 00085472 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (91)

References (23)

1
- 0029644482
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
- (1995) Lancet , vol.345 , pp. 939-949
- Mansoni, S.¹

2
- 0026721532
- Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
- (1992) J. Clin. Oncol. , vol.10 , pp. 896-903

3
- 0026006962
- Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
- (1991) J. Clin. Oncol. , vol.9 , pp. 1967-1972
- Poon, M.A.¹ O'Connell, M.J.² Wieand, H.S.³ Krook, J.E.⁴ Gerstner, J.B.⁵ Tschetter, L.K.⁶ Levitt, R.⁷ Kardinal, C.G.⁸ Mailliard, J.A.⁹

4
- 0031938504
- Rationale for treatment design: Biochemical modulation of 5-fluorouracil by leucovorin
- (1998) Cancer J. Sci. Am. , vol.4 , pp. 12-18
- Rustum, Y.M.¹ Cao, S.² Zhang, Z.³

5
- 0029919598
- Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
- (1996) J. Clin. Oncol. , vol.14 , pp. 709-715
- Conti, J.A.¹ Kemeny, N.E.² Saltz, L.B.³ Huang, Y.⁴ Tong, W.P.⁵ Chou, T.-C.⁶ Sun, M.⁷ Pulliam, S.⁸ Gonzalez, C.⁹

6
- 0031014627
- Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
- (1997) J. Clin. Oncol. , vol.15 , pp. 251-260
- Rougier, P.¹ Bugat, R.² Douillard, J.Y.³ Culine, S.⁴ Suc, E.⁵ Brunet, P.⁶ Becouarn, Y.⁷ Ychou, M.⁸ Marty, M.⁹ Extra, J.M.¹⁰ Bonneterre, J.¹¹ Adenis, A.¹² Seitz, J.F.¹³ Ganem, G.¹⁴ Namer, M.¹⁵ Conroy, T.¹⁶ Negrier, S.¹⁷ Merrouche, Y.¹⁸ Burki, F.¹⁹ Mousseau, M.²⁰ Herait, P.²¹ Mahjoubi, M.²² more..

7
- 0030818926
- Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
- (1997) J. Clin. Oncol. , vol.15 , pp. 2910-2919
- Pitot, H.C.¹ Wender, D.B.² O'Connell, M.J.³ Schroeder, G.⁴ Goldberg, R.M.⁵ Rubin, J.⁶ Mailliard, J.A.⁷ Knost, J.A.⁸ Ghosh, C.⁹ Kirschling, R.J.¹⁰ Levitt, R.¹¹ Windschitl, H.E.¹²

8
- 0029966672
- Phase II trial of irinotecan (CPT-11) in patients with progressive or rapidly recurrent colorectal cancer
- (1996) J. Clin. Oncol. , vol.14 , pp. 1128-1135
- Rothenberg, M.L.¹ Eckardt, J.R.² Kuhn, J.G.³ Burris III, H.A.⁴ Nelson, J.⁵ Hilsenbeck, S.G.⁶ Rodriguez, G.I.⁷ Thurman, A.M.⁸ Smith, L.S.⁹ Eckhardt, S.G.¹⁰ Weiss, G.R.¹¹ Elfring, G.L.¹² Rinaldi, D.A.¹³ Schaaf, L.J.¹⁴ Von-Hoff, D.D.¹⁵

9
- 0025996996
- Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT- 11, in the antitumor effect of CPT-11
- (1991) Cancer Res. , vol.51 , pp. 4187-4191
- Kawato, Y.¹ Aonuma, M.² Hirota, Y.³ Kuga, H.⁴ Sato, K.⁵

10
- 0029841505
- Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
- (1996) Drugs , vol.52 , pp. 606-623
- Wiseman, L.R.¹ Markham, A.²

11
- 0008461578
- Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
- (1996) J. Clin. Oncol. , vol.14 , pp. 2959-2967
- Saltz, L.B.¹ Kanowitz, J.² Kemeny, N.E.³ Schaaf, L.⁴ Spriggs, D.⁵ Staton, B.A.⁶ Berkery, R.⁷ Steger, C.⁸ Eng, M.⁹ Dietz, A.¹⁰ Locker, P.¹¹ Kelsen, D.P.¹²

12
- 0032977698
- Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
- (1999) J. Clin. Oncol. , vol.17 , pp. 907-913
- Vanhoefer, U.¹ Harstrick, A.² Köhne, C.-H.³ Achterrath, W.⁴ Rustum, Y.M.⁵ Seeber, S.⁶ Wike, H.⁷

13
- 0031771777
- Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity
- (1998) Biochem. Pharmacol. , vol.56 , pp. 1315-1322
- Pavillard, V.¹ Formento, P.² Rostagno, P.³ Formento, J.-L.⁴ Fischel, J.-L.⁵ Francoual, M.⁶ Etienne, M.-C.⁷ Milano, G.⁸

14
- 0000534595
- Schedule-dependent antitumor efficacy of irinotecan (CPT-11) in 5-FU resistant human colon tumor xenograft HT29R1
- (1999) Proc. Am. Assoc. Cancer Res. , vol.40 , pp. 110
- Vanhoefer, U.¹ Hapke, G.² Harstrick, A.³ Achterrath, W.⁴ Rustum, Y.M.⁵ Seeber, S.⁶

15
- 0031588364
- Sequence dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo
- (1997) Int. J. Cancer , vol.73 , pp. 729-734
- Guichard, S.¹ Cussac, D.² Hennebelle, I.³ Bugat, R.⁴ Canal, P.⁵

16
- 0028281781
- 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma
- (1994) Cancer Res. , vol.54 , pp. 1507-1510
- Cao, S.¹ Rustum, Y.M.² Spector, T.³

17
- 0000389059
- Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC)
- (1999) Proc. Am. Soc. Clin. Oncol. , vol.18
- Saltz, L.B.¹ Locker, P.K.² Pirotta, N.³ Elfring, G.L.⁴ Miller, L.L.⁵

18
- 0032833697
- Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
- (1999) J. Clin. Oncol. , vol.17 , pp. 2901-2908
- Ducreux, M.¹ Ychou, M.² Seitz, J.-F.³ Bonnay, M.⁴ Bexon, A.⁵ Armand, J.-P.⁶ Mahjoubi, M.⁷ Méry-Mignard, D.⁸ Rougier, P.⁹

19
- 0031949701
- Schedule-dependent synergism between Ralititrexed and irinotecan in human colon cancer in vitro
- (1998) Clin. Cancer Res. , vol.4 , pp. 1323-1330
- Aschele, C.¹ Baldo, C.² Sobrero, A.F.³ Dabernardis, D.⁴ Bornmann, W.G.⁵ Bertino, J.R.⁶

20
- 0031684654
- Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
- (1998) Cancer Chemother. Pharmacol. , vol.42 , pp. 391-399
- Mullany, S.¹ Svingen, P.A.² Kaufmann, S.H.³ Erlichman, C.⁴

21
- 0032032201
- Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
- (1998) Biochem. Pharmacol. , vol.56 , pp. 667-676
- Guichard, S.¹ Hennebelle, I.² Bugat, R.³ Canal, P.⁴

22
- 0029929430
- Role of fluoropyrimidine schedule and (6R, S)-leucovorin dose in a preclinical animal model of colorectal carcinoma
- (1996) J. Natl. Cancer Inst. , vol.88 , pp. 430-436
- Cao, S.¹ Frank, C.² Rustum, Y.M.³

23
- 0032146257
- Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model
- (1998) Cancer Res. , vol.58 , pp. 3270-3274
- Cao, S.¹ Black, J.D.² Troutt, A.B.³ Rustum, Y.M.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.